Danicopan

A detailed overview of the drug Danicopan

Danicopan
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Danicopan is an investigational oral medication that acts as a complement factor D inhibitor. It is primarily being studied for its potential use in treating paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disorder.

Mechanism of Action

Danicopan functions by inhibiting the activity of complement factor D, a serine protease that plays a crucial role in the activation of the alternative complement pathway. By blocking this pathway, Danicopan prevents the formation of the membrane attack complex, thereby reducing hemolysis and other symptoms associated with PNH.

Clinical Development

Danicopan is currently undergoing clinical trials to evaluate its efficacy and safety in patients with PNH. Early studies have shown promising results, with significant reductions in hemolysis and improvements in hemoglobin levels. The drug is being developed by Alexion Pharmaceuticals, a company known for its focus on rare diseases.

Pharmacokinetics

Danicopan is administered orally, which offers a convenient alternative to intravenous therapies currently used for PNH. The pharmacokinetic profile of Danicopan includes rapid absorption and a half-life that supports once or twice daily dosing. This makes it a potentially attractive option for long-term management of PNH.

Side Effects

The most common side effects observed in clinical trials include headache, nausea, and fatigue. As with any investigational drug, ongoing studies are essential to fully understand the safety profile of Danicopan.

Potential Benefits

The development of Danicopan represents a significant advancement in the treatment of PNH. Its oral administration and targeted mechanism of action could improve patient compliance and quality of life compared to existing therapies.

Related pages

• Paroxysmal nocturnal hemoglobinuria
• Complement system
• Alexion Pharmaceuticals